GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArcticZymes Technologies ASA (FRA:B4V) » Definitions » Debt-to-Asset

ArcticZymes Technologies ASA (FRA:B4V) Debt-to-Asset : 0.03 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is ArcticZymes Technologies ASA Debt-to-Asset?

ArcticZymes Technologies ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.32 Mil. ArcticZymes Technologies ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.60 Mil. ArcticZymes Technologies ASA's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €29.72 Mil. ArcticZymes Technologies ASA's debt to asset for the quarter that ended in Mar. 2024 was 0.03.


ArcticZymes Technologies ASA Debt-to-Asset Historical Data

The historical data trend for ArcticZymes Technologies ASA's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArcticZymes Technologies ASA Debt-to-Asset Chart

ArcticZymes Technologies ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.05 0.06 0.04 0.04

ArcticZymes Technologies ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.03

Competitive Comparison of ArcticZymes Technologies ASA's Debt-to-Asset

For the Biotechnology subindustry, ArcticZymes Technologies ASA's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ArcticZymes Technologies ASA's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ArcticZymes Technologies ASA's Debt-to-Asset falls into.



ArcticZymes Technologies ASA Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ArcticZymes Technologies ASA's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

ArcticZymes Technologies ASA's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ArcticZymes Technologies ASA  (FRA:B4V) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


ArcticZymes Technologies ASA Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ArcticZymes Technologies ASA's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ArcticZymes Technologies ASA (FRA:B4V) Business Description

Traded in Other Exchanges
Address
Sykehusveien 23, Tromso, NOR, N-9294
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments that are Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA.

ArcticZymes Technologies ASA (FRA:B4V) Headlines

No Headlines